Cell populations which co-express CD49c and CD90

• US 20050233452A1
• Filed: 02/10/2005
• Published: 10/20/2005
• Est. Priority Date: 09/21/2001
• Status: Active Grant

• Current Assignee: Garnet Biotherapeutics Incorporated
• Original Assignee: Neuronyx, Inc. (Garnet Biotherapeutics Incorporated)
• Inventors: Righter, William F., Ho, Tony W., Rutkowski, J. Lynn, Kopen, Gene C., Wagner, Joseph
• Granted Patent: US 8,486,696 B2
• Time in Patent Office: Days
• US Class Current: 435/372
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/02 Atmosphere, e.g. low oxygen conditions
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0623 Stem cells
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0669 Bone marrow stromal cells; Whole bone marrow isolated stem cells from bone marrow C12N5/0647, C12N5/0663

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

Claims

1. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm² under a low oxygen condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

2. The method of claim 1, wherein the source of the cell population is bone marrow.

3. The method of claim 1, wherein the bone marrow is human bone marrow.

4. The method of claim 1, wherein the low oxygen condition is less than about 15% oxygen.

5. The method of claim 4, wherein the low oxygen condition is about is less than about 10% oxygen.

6. The method of claim 1, wherein the low oxygen condition is about 5% oxygen.

7. The method of claim 2, further including lysing the bone marrow prior to culturing the bone marrow.

8. The method of claim 2, further including fractionating the bone marrow prior to culturing the bone marrow.

9. The method of claim 8, wherein in the bone marrow is fractionated by passage through a density gradient.

10. The method of claim 8, wherein the bone marrow is fractionated by NH₂Cl lysis.

11. The method of claim 8, wherein the bone marrow is fractionated by fluorescent activated sorting.

12. The method of claim 8, wherein the bone marrow is fractionated by magnetic sorting.

13. The method of claim 1, wherein the cells which co-express CD49c and CD90 do not express CD34 and/or CD45.

14. The method of claim 1, wherein the cells selected from the cultured source express at least one trophic factor selected from the group consisting of BDNF, IL-6, NGF and MCP-1.

15. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm² under a low oxidative stress condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

16. The method of claim 15, wherein the source of the cell population is bone marrow.

17. The method of claim 15, wherein the bone marrow is human bone marrow.

18. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm² under a low oxidative stress condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

19. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm² under a low oxidative stress condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

20. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm² under a low oxygen condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.

21. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:

a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm² under a low oxygen condition; and

b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.